Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Actonel)
2,150 results
  • Bisphosphonates for osteoporosis in people with cystic fibrosis. [Review]
    Cochrane Database Syst Rev. 2023 01 10; 1:CD002010.Jeffery TC, Chang AB, Conwell LS
  • CONCLUSIONS: Oral and intravenous bisphosphonates may increase bone mineral density in people with cystic fibrosis, but there are insufficient data to determine whether treatment reduces fractures. Severe bone pain and flu-like symptoms may occur with intravenous bisphosphonates. Before any firm conclusions can be drawn, trials in larger populations, including children, and of longer duration are needed to determine effects on fracture rate and survival. Additional trials are needed to determine if bone pain is more common or severe (or both) with the more potent zoledronate and if corticosteroids can ameliorate or prevent these adverse events. Future trials should also assess gastrointestinal adverse effects associated with oral bisphosphonates.
  • The Use of Polymers to Enhance Post-Orthodontic Tooth Stability. [Review]
    Polymers (Basel). 2022 Dec 27; 15(1)Rosyida NF, Ana ID, Alhasyimi AA
  • Relapse after orthodontic treatment occurs at a rate of about 70 to 90%, and this phenomenon is an orthodontic issue that has not yet been resolved. Retention devices are one attempt at prevention, but they require a considerable amount of time. Most orthodontists continue to find it challenging to manage orthodontic relapse; therefore, additional research is required. In line with existing knowl…
  • Risedronate-loaded aerogel scaffolds for bone regeneration. [Journal Article]
    Drug Deliv. 2023 Dec; 30(1):51-63.El-Wakil N, Kamel R, … Maged A
  • Sugarcane bagasse-derived nanofibrillated cellulose (NFC), a type of cellulose with a fibrous structure, is potentially used in the pharmaceutical field. Regeneration of this cellulose using a green process offers a more accessible and less ordered cellulose II structure (amorphous cellulose; AmC). Furthermore, the preparation of cross-linked cellulose (NFC/AmC) provides a dual advantage by build…
  • Ocular Side Effects of Bisphosphonates: A Review of Literature. [Review]
    J Ocul Pharmacol Ther. 2023 Jan-Feb; 39(1):3-16.Chartrand NA, Lau CK, … Moshirfar M
  • In rare cases, bisphosphonates are well established to cause ocular inflammation, presenting as uveitis, episcleritis, scleritis, orbital inflammation, and/or conjunctivitis. Some reports of bisphosphonate-associated neuro-ophthalmic complications also exist. We identified 101 reports in the literature relating to bisphosphonate-associated ocular complications. In a great majority of cases, sympt…
  • Chitosan - zeolite scaffold as a potential biomaterial in the controlled release of drugs for osteoporosis. [Journal Article]
    Int J Biol Macromol. 2022 Dec 31; 223(Pt A):812-820.Sandomierski M, Adamska K, … Voelkel A
  • Chitosan scaffolds are a potential material in many biomedical applications. A particularly interesting application is their use in bone tissue engineering. Because of their biocompatibility and nontoxicity, they are an ideal material for this application. What is missing from chitosan scaffolds is controlled drug release. They can obtain this property by adding drug carriers. In this work, chito…
  • Novel formulations of oral bisphosphonates in the treatment of osteoporosis. [Review]
    Aging Clin Exp Res. 2022 Nov; 34(11):2625-2634.Fuggle N, Al-Daghri N, … Cooper C
  • Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel …
  • Polypharmacy in Osteoporosis Treatment. [Review]
    Clin Geriatr Med. 2022 11; 38(4):715-726.McConnell M, Shieh A
  • In older adults, polypharmacy and osteoporosis frequently occur contemporaneously. Polypharmacy is increasingly recognized as a risk factor for hip and fall-related fractures. Treatments for osteoporosis include antiresorptive (alendronate, risedronate, zoledronic acid, ibandronate, denosumab) and osteoanabolic (teriparatide, abaloparatide, romosozumab) agents. Polypharmacy is associated with wor…
  • Medication-Related Osteonecrosis of the Jaw: 14 Years' Retrospective Study on Pathogenetic Trigger Events. [Journal Article]
    J Craniofac Surg. 2022 Oct 01; 33(7):e771-e776.Marino R, Squillacioti A, … Nastro Siniscalchi E
  • Although events such as tooth extraction and oral surgery were considered for a while the sole triggering factor for Medication-Related Osteonecrosis of the Jaw (MRONJ), it is still unclear if trigger events may be precipitating factors that accelerate the onset of the disease that would have possibly occurred anyway. Therefore, this research aimed to retrospectively analyze MRONJ cases diagnosed…
  • DEVELOPMENT AND ESTIMATION OF HUMAN DOSIMETRY OF A NEW 47SC-RISEDRONATE FOR RADIOPHARMACEUTICAL APPLICATION. [Journal Article]
    Radiat Prot Dosimetry. 2022 Oct 16; 198(19):1483-1494.Moghaddam-Banaem L, Deilami-Nezhad L, … Jalilifar M
  • Bisphosphonate risedronate (2-(3-pyridinyl)-1-hydroxyethane diphosphonic acid) was radiolabeled with scandium-47 (47Sc) as potential therapeutic radiopharmaceutical for skeletal metastases. Its time-dependent biodistribution in mice was measured and its human dosimetry was derived. The labelling process was performed at 95 °C for 30 min. The stability of the radio-conjugate was tested in human se…
New Search Next